Upfront ASCT Still Best Option in Newly Diagnosed Multiple Myeloma
June 23rd 2016In this video we discuss the results of a phase III trial that studied upfront high-dose chemotherapy plus autologous stem cell transplantation (ASCT) compared to chemotherapy alone and bortezomib in newly diagnosed multiple myeloma.
EXAM: Cabozantinib Doubled Survival in Medullary Thyroid Carcinoma With RET M918T Mutation
June 10th 2015In this video, Steven I. Sherman, MD, discusses the final overall survival analysis of the EXAM study, a randomized, placebo-controlled phase III trial of cabozantinib in medullary thyroid carcinoma patients.